Neurocrine Announces Proposed Public Offering of Common Stock

Neurocrine Biosciences, Inc. (Nasdaq:NBIX – News) today announced that it is offering to sell shares of its common stock in an underwritten public offering.  Jefferies & Company, Inc. is the sole book-running manager for this offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

{loadposition in-article}

The securities described above are being offered by Neurocrine pursuant to a shelf registration statement previously filed with and declared effective by the Securities and Exchange Commission (the “SEC”) on December 3, 2007. A preliminary prospectus supplement related to the offering has been filed with the SEC and is available on the SEC’s Web site at [Read the full article]

Solar Capital Ltd. (NASDAQ: SLRC – News), today reported results for the year ended December 31, 2009. Pro-forma1 net asset value per share was $21.50, the top end of the estimated range provided in the Company prospectus related to its initial public offering. On February 9, 2010, Solar Capital priced its IPO and completed a merger with Solar Capital LLC. [Read the full article]

Non-GAAP net income* increased to $3.5 million and $11.7 million in Q4 and full year, respectively

GAAP net income increased to $1.7 million and $5.2 million in Q4 and full year, respectively

Medidata Solutions (NASDAQ: MDSO – News), a leading global provider of hosted clinical development solutions, today announced its financial results for the fourth quarter and full year ended December 31, 2009 and provided financial guidance for 2010.

“Medidata concluded 2009 with impressive execution and strong financial performance across the board. We further solidified our position as a market leader and have set the stage for an excellent 2010, based on our premier customer base, expanded backlog, rapidly scaling profitability and overall momentum,” noted Tarek Sherif, chairman and chief executive officer of Medidata Solutions. [Read the full article]

Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH – News), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced the completion of its initial public offering of six million shares of common stock at a price of $7.00 per share.  The net proceeds of the offering to Anthera, after deducting underwriting discounts and commissions and estimated offering expenses payable by Anthera, were approximately $36.7 million. In addition, Anthera has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares to cover over-allotments, if any. The sole book-running manager of the offering is Deutsche Bank Securities Inc. Piper Jaffray & Co. is a co-lead manager of the offering and Cowen and Company, LLC and Merriman Curhan Ford & Co. are co-managers of the offering. [Read the full article]

You may also like...